Excision BioTherapeutics Announces Publication Highlighting EBT-107 for the Treatment of Chronic Hepatitis B in bioRxiv

Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced publication of a preprint demonstrating proof-of-concept studies of EBT-107, a therapeutic candidate for chronic hepatitis B in bioRxiv.